Effects of antibodies against octreotide in two patients with acromegaly
- 1 May 1991
- journal article
- case report
- Published by Wiley in Clinical Endocrinology
- Vol. 34 (5) , 395-398
- https://doi.org/10.1111/j.1365-2265.1991.tb00311.x
Abstract
Two patients developed specific IgG antibodies against octreotide after 2-3 years' treatment for acromegaly with this long acting somatostatin analogue. The presence of these antibodies reduced the plasma disappearance rate of total extractable octreotide by 60 and 80% respectively. When compared to that of non-immune acromegalic patients, the plasma half-life of octreotide in these two patients was 300 and 450 vs 110 min in those with no detectable octreotide antibodies. The sole observed consequence of the immunization was a marked prolongation of the interval of maximum GH inhibition from a mean of 5 to 8 and 10 h in the two patients described after octreotide injection.Keywords
This publication has 6 references indexed in Scilit:
- Lack of antibody formation during long-term subcutaneous treatment with the somatostatin analogue octreotide in acromegalyActa Endocrinologica, 1990
- Observations During a Clinical Trial of Sandostatin® in Acromegalic PatientsPublished by Springer Nature ,1988
- Chronic administration of the somatostatin analogue SMS 201–995 does not lead to endogenous antibody formationAlimentary Pharmacology & Therapeutics, 1987
- Insulin resistance in uraemic insulin-dependent diabetics Effect of dialysis therapy as assessed by the artificial endocrine pancreasActa Endocrinologica, 1984
- Detection of M-components by an easy immunofixation procedure: Comparison with agarose gel electrophoresis and classical immunoelectrophoresisJournal of Immunological Methods, 1979
- Wick Chromatography for Rapid and Reliable Immunoassay of Insulin, Glucagon and Growth HormoneNature, 1968